Radiotherapy in low-grade gliomas: pros. 2003

Rolf-Dieter Kortmann
Department of Radiotherapy, Hoppe-Seyler-Str 3, D-72076 Tuebingen, Germany.

Although surgery is generally accepted as an important initial treatment in patients with low-grade gliomas, the role of postoperative radiotherapy (RT) is the subject of ongoing controversy. What is the most appropriate timing of RT? Is it best to deliver RT immediately after surgery or to watch and wait until disease progression? Numerous retrospective studies have shown that immediate postoperative RT provides a survival benefit. A recently published prospective study conducted by the European Organisation for Research and Treatment of Cancer has also shown that immediate postoperative RT significantly improved 5-year progression-free survival, but overall survival was not improved. Given the uncertainty about the overall survival benefit of immediate RT and the potential for radiation-induced toxicity, it is important to consider prognostic factors when selecting patients. Subgroups of patients with poor prognostic factors are more likely to benefit from immediate postoperative RT. Available data indicate that a carefully balanced therapeutic approach is needed to optimize treatment outcomes in patients with low-grade gliomas. Patients with more aggressive disease and a high risk of malignant transformation will likely benefit from immediate RT, whereas patients with low-risk disease, particularly oligodendrogliomas, can reasonably be observed. However, one cannot exclude the possibility that delaying RT may result in a worse long-term clinical outcome.

UI MeSH Term Description Entries
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D018714 Radiotherapy, Adjuvant Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. Adjuvant Radiotherapy,Adjuvant Radiotherapies,Radiotherapies, Adjuvant

Related Publications

Rolf-Dieter Kortmann
December 2003, Seminars in oncology,
Rolf-Dieter Kortmann
January 2002, Acta medica portuguesa,
Rolf-Dieter Kortmann
January 2015, Pediatric blood & cancer,
Rolf-Dieter Kortmann
March 1989, International journal of radiation oncology, biology, physics,
Rolf-Dieter Kortmann
March 2023, PLoS computational biology,
Rolf-Dieter Kortmann
May 1995, Annals of neurology,
Rolf-Dieter Kortmann
June 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
Rolf-Dieter Kortmann
January 2010, Advances and technical standards in neurosurgery,
Rolf-Dieter Kortmann
August 2009, Current treatment options in oncology,
Copied contents to your clipboard!